Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2003-06-16
2009-02-24
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S139100, C424S141100, C424S145100, C435S007100, C435S007920
Reexamination Certificate
active
07494647
ABSTRACT:
A humanized antibody against tissue factor (TF), comprising:A: a humanized H chain comprising (1) a H chain V region comprising the H chain CDRs of a mouse monoclonal antibody against TF and the H chain FRs of a human antibody, and (2) the H chain C region of a human antibody; andB: a humanized L chain comprising (1) an L chain V region comprising the L chain CDRs of a mouse monoclonal antibody against TF and the L chain FRs of a human antibody, and (2) the L chain C region of a human antibody.After generating a humanized V region by grafting the CDRs of a mouse monoclonal antibody onto a human antibody, a humanized antibody having a higher activity is searched by replacing the FR of the above region with the corresponding FR of the human antibody having a high homology.
REFERENCES:
patent: 5223427 (1993-06-01), Morrissey et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 0 239 400 (1994-08-01), None
patent: 1-503438 (1989-11-01), None
patent: 4-505398 (1992-09-01), None
patent: WO 88/07543 (1988-10-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/09968 (1991-07-01), None
patent: WO 91/16928 (1991-11-01), None
patent: WO 94/05328 (1994-03-01), None
patent: WO 94/05328 (1994-03-01), None
patent: WO 94/11029 (1994-05-01), None
patent: WO 94/11523 (1994-05-01), None
patent: WO 96/40921 (1996-12-01), None
patent: WO 96/40921 (1996-12-01), None
Singer et al., “Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences” 1993, J Immunol, 150:2844-2857.
Janeway et al., Immunobiology, third edition, Garland Publishing Inc., 1997, pp. 3:2-3:9.
Gavilondo et al. “Antibody engineering at the millennium” BioTechniques, 2000, 29:128-145.
Hiroshi Noguchi “Theory and Clinical Application of Chimera Antibody and Humanized Antibody,”Journal of Clinical and Experimental Medicine, 167: 457-462 (1993).
Ruf et al, “Purification, sequence and crystallization of an anti-tissue factor Fab and its use for the Crystallization of tissue factor”, J. of Crystal Growth 122 (1992), pp. 253-264, Elsevier Science. Pub. B.V.
Maeda et al, “Construction of reshaped human antibodies with HIV-neutralizing activity”, Hum. Antibod. Hybridomas, vol. 2 (1991), pp. 124-134, Butterworth-Heinemann.
Hougs et al, “Rapid analysis of rearranged Kappa light chain genes of circulating polysaccharide-specific B Lymphocytes by means of immunomagnetic beads and the polymerase chain reaction”, Exp. Clin. Immunogenet, 10 (1993), pp. 141-151, S. Karger AG, Basel.
Epp et al, “The molecular structure of a dimer composed of the variable portions of the Bence-Jones Protein REI refined at 2.0-{dot over (a)} Resolution”, Biochemistry, vol. 14, No. 22, (1975), pp. 4943-4952, Max-Planck Institute.
Bejeck et al, “Development and characterization of three recombinant single chain antibody fragments (scFvs) Directed against the CD19 antigen1” Cancer Research 55, (1995), pp. 2346-2351.
Sato et al, Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth1Cancer Research 53, (1993), pp. 851-856.
Welschof et al, “Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes”, J. of Immunological Methods 179, (1995) pp. 203-214 Elsevier Science B.V.
Tempest et al, “Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus Infection in vivo”, Bio/Technology vol. 9 (1991) pp. 266-271, Scotgen Limited.
Kettleborough et al, “Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of Framework residues on loop conformation”, Protein Engineering vol. 4, No. 7 (1991) pp. 773-783 Oxford University Press.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 492-495.
Kuby et al., Immunology, Second Edition, 1994, pp. 86-96.
Colman et al., A structural View of Immune Recognition by Antibodies, 1994, pp. 33-36.
Cunningham et al, “The covalent structure of a human γG-Immunoglobulin. VII. Amino Acid Sequence of Heavy-Chain Cyanogen Bromide Fragments H1-H4*”, Biochemistry, vol. 9, No. 16, (1970), Rockerfeller Univ.
Poljak et al, Amino Acid sequence of the VH Region of a human myeloma immunoglobulin (IgG New) BioChemistry vol. 16, No. 15, (1977) pp. 3412-3420.
Tonge et al, “Cloning and characterization of 1116NS19.9 heavy and light chain cDNAs and expression of Antibody fragments inEscherichia coll”, Terhorst C, Malavasi F, Albertini A (eds): Generation of Antibodies by Cell and Gene Immortalizaiton, Year Immunol. Basel, Karger, vol. 7, pp. 56-62 (1993).
Man Sung Co et al, “Humanized antibodies for antiviral therapy”, Proc. Natl. Acad. Sci., vol. 88, pp. 2869-2873 (1991), Protein Design Labs, Inc.
Gorman et al, “Reshaping a therapeutic CD4 antibody”, Proc. Natl. Acad. Sci. vol. 88, pp. 4181-4185 (1991) Dept of Pathology, Univ of Cambridge.
Collet et al, “A binary plasmid system for shuffling combinatorial antibody libraries”, Proc. Natl. Acad. Sci. vol. 89, pp. 10026-10030 (1992), Dept. of Chemistry & Molecular Biology.
Borretzen et al, “Control of autoantibody affinity by selection against amino acid replacements in the Complementarity-determining regions”, Proc. Natl. Acad. Sci., vol. 91, pp. 12917-12921 (1994).
Verhoeyen et al, “Reshaping human antibodies: grafting an antilysozyme activity”, Science vol. 239 (1988) Medical research council lab. Of molecular biology.
Ito et al, “Characterization of functionally important regions of tissue factor by using monoclonal antibodies”, J. Biochem. vol. 114, No. 5, pp. 691-696, (1993), Dept. of Molecular Biology.
Pascual et al, “The complete nucleotide sequences of the heavy chain variable regions of six monospecific Rheumatoid factors derived from epstein-barr virus-transformed B cells isolated from the synovial tissue Of patients with rheumatoid arthritis”, J. Clin. Invest. (1990), vol. 86, pp. 1320-1328, Amer.Soc. of Clin. Invt.
N. van der Stoep et al, “Molecular evolution of the human immunoglobulin E response: high incidence of Shared mutations and clonal relatedness among ε VH5 transscripts from three unrelated patients with atopic Dermatitis”, J. Exp. Med., vol. 177, (1993) pp. 99-107, The Rockerfeller University Press.
Hillson et al, “The structural basis of germline-encoded VH3 Immunoglobulin binding to staphylococcal Protein A”, J. Exp. Med., vol. 178, (1993) pp. 331-336, The Rockerfeller University Press.
Man Sung CO et al, “Chimeric and humanized antibodies with specificity for the CD33 antigen”, J. of Immun. vol. 148, No. 4, pp. 1149-1154, (1992), Amer. Assoc. of Immunologists.
Riechmann et al, “Reshaping human antibodies for therapy”, Nature, vol. 332, pp. 323-327 (1988) Dept. of Molecular Biology, The research institute of Scripps Clinic.
Cox et al, “A directory of human germ-line Vxsegments reveals a strong bias in their usage”, Eur. J. Immunol. 24:827-823, (1994), VCH Verlagsgesellschaft mbH.
Carter et al, “Humanization of an anti-p185RER2antibody for human cancer therapy”, Proc. Natl. Acad. Sci. vol. 89, pp. 4285-4289, (1992).
Adachi Hideki
Sato Koh
Yabuta Naohiro
Chugai Seiyaku Kabushiki Kaisha
Foley & Lardner LLP
Szperka Michael
LandOfFree
Humanized antibody against human tissue factor (TF) and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized antibody against human tissue factor (TF) and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibody against human tissue factor (TF) and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4128797